Compositions containing D-chiro-inositol

A surfactant-containing composition stabilizes D-chiro-inositol in aqueous solutions, preventing precipitation and improving application feel.

JP7580183B2Active Publication Date: 2024-11-11KOBAYASHI PHARMA CO LTD
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
JP2018125156
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Filing Date
2018-06-29
Publication Date
2024-11-11
Estimated Expiration
2038-06-29

AI Technical Summary

Technical Problem

D-chiro-inositol tends to easily generate precipitates in aqueous solutions, limiting its effective use in compositions.

Method used

A composition containing D-chiro-inositol, a surfactant, and water, with specific surfactant types and concentrations, suppresses precipitation and improves solubility.

Benefits of technology

The composition effectively prevents precipitation of D-chiro-inositol, enhancing its usability and providing a better feel during application.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007580183000001
    Figure 0007580183000001
Patent Text Reader

Abstract

To provide a composition capable of suppressing precipitation of D-chiro-inositol.SOLUTION: There is provided a composition comprising D-chiro-inositol, a surfactant and water.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a composition containing D-chiro-inositol. The present invention also relates to an external preparation containing the composition. [Background technology]

[0002] Inositol (1,2,3,4,5,6-cyclohexanehexaol) has a structure in which one hydrogen atom on each carbon of the cyclohexane is replaced by a hydroxyl group, and is known as a vitamin-like substance. Inositol exists in nine stereoisomers, depending on the combination of the configuration of the hydroxyl groups.

[0003] Patent Document 1 discloses a hair growth agent containing inositol as an active ingredient. As in Patent Document 1, the term "inositol" used in the prior art generally means a stereoisomer of myo-inositol (cis-1,2,3,5-trans-4,6-cyclohexanehexaol) as an additive for drugs, quasi-drugs, cosmetics, etc. (see, for example, Non-Patent Documents 1 to 3). Furthermore, the present inventors have found that, among the stereoisomers of inositol, chiro-inositol is a compound useful as a hair growth agent (see Patent Document 2). [Prior art documents] [Patent documents]

[0004] [Patent Document 1] JP 2006-28026 A [Patent Document 2] International Publication No. 2017 / 188393 [Non-patent literature]

[0005] [Non-Patent Document 1] Quasi-drug Raw Materials Standards 2006 Integrated Edition, Yakuji Nipposha, p.318 [Non-Patent Document 2] Pharmaceutical Additives Standards 2003, Yakuji Nipposha, p.101-102 [Non-Patent Document 3] Pharmaceutical Additives Encyclopedia 2000, Yakuji Nipposha, p.26 Summary of the Invention [Problem to be solved by the invention]

[0006] Here, the present inventors have found that, among the stereoisomers of inositol, D-chiro-inositol is a compound that is water-soluble among the isomers of inositol. However, while continuing to conduct research into compositions containing D-chiro-inositol in order to take advantage of these properties of D-chiro-inositol, it was discovered that, among the stereoisomers of inositol, D-chiro-inositol is more likely to form precipitates in aqueous solutions.

[0007] Therefore, an object of the present invention is to provide a composition capable of inhibiting the precipitation of D-chiro-inositol. [Means for solving the problem]

[0008] As a result of extensive research to solve the above problems, the inventors have discovered that a composition further containing a surfactant is capable of inhibiting the precipitation of D-chiro-inositol in an aqueous solution containing D-chiro-inositol, and have thus completed the present invention.

[0009] That is, the present invention provides the following inventions. [1] A composition comprising D-chiro-inositol, a surfactant, and water. [2] The composition according to [1], wherein the content of D-chiro-inositol is 0.001 to 20% by mass. [3] The composition described in [1] or [2], wherein the surfactant comprises a nonionic surfactant. [4] The composition according to any one of [1] to [3], wherein the surfactant has an HLB value of 2 to 17. [5] The composition according to any one of [1] to [4], wherein the nonionic surfactant comprises polyoxyethylene hydrogenated castor oil or polyoxyethylene polyoxypropylene alkyl ether. [6] An external preparation comprising the composition described in any one of [1] to [5]. [7] An external preparation for scalp comprising the composition described in any one of [1] to [5]. Effect of the Invention

[0010] According to the present invention, there is provided a composition capable of inhibiting the precipitation of D-chiro-inositol. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0011] The present invention will be clarified by describing the composition of the present invention and specific embodiments thereof below. However, the present invention is not limited to the specific embodiments described below.

[0012] The composition of the present invention comprises D-chiro-inositol, a surfactant, and water.

[0013] D-chiro-inositol is not particularly limited, but examples thereof include those extracted from naturally occurring buckwheat, beans, citrus fruits, etc., those extracted and purified from legumes by fermentation, those chemically synthesized, and commercially available products. Here, the extraction method is not particularly limited, and known extraction methods can be used.

[0014] The content of D-chiro-inositol in the composition of the present invention is not particularly limited, but is preferably 0.001 to 20 mass%, more preferably 0.01 to 20 mass%, even more preferably 0.05 to 15 mass%, still more preferably 1 to 10 mass%, and even more preferably 3 to 7 mass%.

[0015] In this specification, "mass %" refers to the mass percentage of a component contained in a composition relative to the mass of the entire composition. In addition, in this specification, the expression "X to Y" means X or more and Y or less.

[0016] The composition of the present invention can be used as an external preparation, for example, an agent for cracks and chapped skin, an agent for heat rash and sores, an agent for corns and calluses, an agent for dryness and roughness, an agent for wrinkles and age spots, a moisturizer, a hair dye, a hair growth agent, a shampoo, a rinse, a conditioner, a lotion, a cream, a milky lotion, a hand cream, a medicated soap, a pack, and the like. By containing D-chiro-inositol, the composition of the present invention can have vitamin-like effects and hair growth activity, and may be used as a hair growth agent. Specifically, the hair growth activity is activity relating to hair shaft growth promotion, hair growth, hair loss prevention, etc., and is preferably activity relating to hair shaft growth promotion and hair growth.

[0017] The composition of the present invention comprises a surfactant. By including a surfactant, it is possible to suppress the precipitation of D-chiro-inositol in an aqueous solution containing D-chiro-inositol. Furthermore, by including a surfactant in the composition of the present invention, it is possible to improve the feeling of use of a preparation containing the composition of the present invention. It is presumed that the reason for such an effect is that the surfactant improves the solubility of D-chiro-inositol in an aqueous solution (however, the reason is not limited to this).

[0018] The surfactant is not particularly limited, but includes nonionic surfactants, cationic surfactants, anionic surfactants, and amphoteric surfactants. Among these, nonionic surfactants are preferred from the viewpoint of obtaining a good feeling of use. The surfactant may be used alone or in combination of two or more kinds.

[0019] The HLB value of the surfactant is not particularly limited, but is preferably 2 to 17, more preferably 6 to 17, and even more preferably 12 to 17. By using a surfactant with an HLB value in such a range, the precipitation of D-chiro-inositol tends to be reduced. HLB is an abbreviation for hydrophile-lipophile balance, and is one of the indicators of the effect of a surfactant, and the higher the HLB value, the higher the hydrophilicity. The HLB value in the present invention refers to a value calculated by the Davies formula, HLB=7+Σ(number of hydrophilic groups)-Σ(number of lipophilic groups) (hereinafter, the same applies when simply referring to "HLB value"). In addition, when two or more surfactants are contained, the HLB value is the weighted average value of the HLB values ​​of each surfactant.

[0020] The nonionic surfactant refers to a surfactant that does not exhibit ionic properties in an aqueous solution. The nonionic surfactant is not particularly limited, but examples thereof include polyoxyethylene hydrogenated castor oil, polyoxyethylene polyoxypropylene alkyl ether, polyoxyethylene sorbitan oleate, monoester of oleic acid and glycerin, and ester of oleic acid and diglycerin. Among these, polyoxyethylene hydrogenated castor oil and polyoxyethylene polyoxypropylene alkyl ether are preferred from the viewpoint of suppressing the precipitation of D-chiro-inositol and obtaining a good feeling of use.

[0021] The cationic surfactant and the anionic surfactant refer to surfactants that become cations and anions, respectively, when dissociated in an aqueous solution, and the amphoteric surfactant refers to surfactants that become either cations, anions, or zwitterions in an aqueous solution depending on the pH of the aqueous solution. The cationic surfactant is not particularly limited, but examples thereof include alkyl dimethyl amines, alkyl trimethyl ammonium salts, and dialkyl dimethyl ammonium salts. The anionic surfactant is not particularly limited, but examples thereof include fatty acid salts and alkyl sulfate salts. Examples of amphoteric surfactants include, but are not limited to, alkylamino fatty acid salts, alkyl betaines, and alkyl amine oxides.

[0022] The content of the surfactant in the composition of the present invention is not particularly limited, but is usually 0.1 to 10 mass %, preferably 0.5 to 7 mass %, and more preferably 1 to 5 mass %.

[0023] The composition of the present invention may further contain an organic acid or a salt thereof. Although not particularly limited, the composition of the present invention preferably contains an organic acid and a salt of an organic acid. By including an organic acid or a salt thereof, it tends to be possible to improve the feeling of use in a preparation containing the composition of the present invention, even when the preparation further includes a solvent other than water, for example, a monoalcohol having 1 to 3 carbon atoms. The reason for this effect is presumed to be that the organic acid or a salt thereof exerts a chelating effect, and functions to alleviate the irritation contributed by a solvent other than water, for example, a monoalcohol having 1 to 3 carbon atoms (however, the reason is not limited to this).

[0024] The organic acid refers to an organic compound that exhibits acidity in water by itself. The organic acid is not particularly limited as long as it is an organic compound that exhibits acidity, and examples thereof include monocarboxylic acids, polycarboxylic acids, and organic sulfonic acids. Among these, polycarboxylic acids are preferred from the viewpoint of obtaining a good feeling when used.

[0025] A monocarboxylic acid refers to an organic compound having one carboxylic acid in the molecule, and a polycarboxylic acid refers to an organic compound having two or more carboxylic acids in the molecule. An organic sulfonic acid refers to an organic compound having at least one sulfonic acid group in the molecule. The monocarboxylic acid is not particularly limited, but may be, for example, formic acid, acetic acid, propionic acid, and valeric acid. The polycarboxylic acid is not particularly limited, but includes dicarboxylic acids, tricarboxylic acids, tetracarboxylic acids, etc., such as citric acid, edetic acid, phthalic acid, isophthalic acid, terephthalic acid, succinic acid, fumaric acid, maleic acid, malic acid, and tartaric acid. Of these, citric acid and edetic acid are preferred. Organic sulfonic acids include, but are not limited to, methanesulfonic acid, benzenesulfonic acid, and taurine. The salt of the organic acid is not particularly limited, but examples thereof include sodium salts, potassium salts, calcium salts, and magnesium salts. Of these, sodium salts are preferred.

[0026] The organic acid or its salt may be used alone or in combination of two or more. When two or more types are used in combination, the combination may be two or more organic acids, two or more salts of organic acids, or two or more organic acids and salts of organic acids. When an organic acid and a salt of an organic acid are used, the organic acid and the organic acid of the salt of the organic acid may be the same or different, but it is preferable to use the organic acid and the salt of the organic acid in combination.

[0027] The content of the organic acid or a salt thereof in the composition of the present invention is not particularly limited, but is usually 0.001 to 5 mass%, preferably 0.01 to 3 mass%, more preferably 0.03 to 1 mass%, and even more preferably 0.05 to 1 mass%.

[0028] The composition of the present invention comprises water. By including water, the D-chiro-inositol contained in the composition of the present invention can be treated as an aqueous solution.

[0029] Examples of water include pure water such as ion-exchanged water, ultrafiltered water, reverse osmosis water, and distilled water, as well as ultrapure water from which ionic impurities have been removed as much as possible.

[0030] The composition of the present invention may further contain a monoalcohol and / or a polyhydric alcohol having 1 to 3 carbon atoms. By including a monoalcohol and / or a polyhydric alcohol having 1 to 3 carbon atoms, it tends to be possible to obtain a composition having antibacterial properties and moisturizing properties.

[0031] The monoalcohol having 1 to 3 carbon atoms includes methanol, ethanol, n-propanol, and isopropanol, with ethanol and isopropanol being preferred, and ethanol being more preferred. A polyhydric alcohol refers to an alcohol having two or more hydroxyl groups in the molecule. Examples of polyhydric alcohols include, but are not limited to, glycerin, ethylene glycol, diethylene glycol, triethylene glycol, propylene glycol (1,2-propanediol), dipropylene glycol, trimethylolpropane, 1,3-propylene glycol (1,3-propanediol), isobutylene glycol (2-methyl-1,2-propanediol), 1,2-butanediol, 1,3-butylene glycol (1,3-butanediol), 1,4-butanediol, 2-butene-1,4-diol, 1,2-pentanediol, 1,5-pentanediol, 2-methyl-2,4-pentanediol, 1,2-hexanediol, 1,6-hexanediol, 2-ethyl-1,3-hexanediol, 1,7-heptanediol, and 1,8-octanediol. Of these, glycerin, propylene glycol, and 1,3-butylene glycol are preferred. The monoalcohols and polyhydric alcohols having 1 to 3 carbon atoms may each independently be used alone or in combination of two or more kinds.

[0032] The content of the monoalcohol having 1 to 3 carbon atoms in the composition of the present invention is not particularly limited, but it is possible to set the content of the monoalcohol having 1 to 3 carbon atoms high. The content of the monoalcohol having 1 to 3 carbon atoms in the composition of the present invention is usually 80% by mass or less, may be 60% by mass or less, may be 30 to 60% by mass, may be 30 to 50% by mass, or may be 30 to 40% by mass.

[0033] The content of the polyhydric alcohol in the composition of the present invention is not particularly limited, but is usually 0.1 mass% or more, preferably 0.5 mass%, more preferably 0.5 to 30 mass%, even more preferably 0.5 to 20 mass%, and still more preferably 0.5 to 15 mass%.

[0034] The compositions of the present invention may further comprise a monoterpene. By including a monoterpene, a refreshing feeling is imparted and an excellent composition tends to be obtained by suppressing the precipitation of D-chiro-inositol.

[0035] The monoterpene is not particularly limited, but includes monoterpene hydrocarbons such as limonene, pinene, and camphor; monoterpene alcohols such as citronellol, geraniol, linalool, menthol, terpineol, and borneol; monoterpene aldehydes such as citronellal, citral, and safranal; and monoterpene ketones such as menthone, carbomenthone, and ionone. Monoterpene alcohols are preferred, and menthol is more preferred. These monoterpenes may be any of d-, l-, and dl-forms. In particular, menthol is preferably l-menthol or d-menthol, and more preferably l-menthol. A mixture of l-menthol and d-menthol may be used. The monoterpenes may be used alone or in combination of two or more.

[0036] The content of monoterpene in the composition of the present invention is not particularly limited, but is preferably 0.01 to 10 mass%, more preferably 0.05 to 2 mass%, even more preferably 0.1 to 1.0 mass%, and even more preferably 0.7 to 1.0 mass%, because this not only provides a refreshing sensation but also is excellent in inhibiting precipitation of D-chiro-inositol, inhibiting dripping and irritation (tingling sensation) in the resulting composition, and inhibiting separation of the monoterpene itself.

[0037] The composition of the present invention may further contain additives that are generally acceptable for use in drugs, quasi-drugs, cosmetics, and the like. The additives are not particularly limited, but examples thereof include excipients, stabilizers, odorants, bases, dispersants, diluents, emulsifiers, transdermal absorption enhancers, preservatives, colorants, oils (oils and fats, mineral oils, etc.), thickeners, polymers, film-forming agents, UV absorbers, cell activators, antioxidants, preservatives, cooling agents, deodorants, pigments, dyes, fragrances, sugars, amino acids, vitamins, organic acids, organic amines, and plant extracts.

[0038] The composition of the present invention is not particularly limited, and can be produced by mixing the components included in the present invention. The order in which the components are mixed is not particularly limited. The mixing conditions are not particularly limited, and the composition of the present invention can be prepared according to a conventional method.

[0039] When the composition of the present invention is used as an external preparation, it can be used as a medicine, a quasi-drug, a cosmetic, etc. For example, it can be used as an external preparation for skin, an external preparation for hair, and an external preparation for scalp, and more specifically, it can be used as a medicine for skin, a medicine for hair, and a medicine for scalp, a quasi-drug for skin, a quasi-drug for hair, and a quasi-drug for scalp, as well as a cosmetic for skin, a cosmetic for hair, and a cosmetic for scalp. More specifically, it can be in the form of an ointment, a cataplasm, a liniment, a lotion, an external liquid, a dusting agent, a cream, a gel, an emulsion, a hair tonic, or a hairspray. In this specification, "external preparations for hair" and "external preparations for scalp" may be used in the same or different forms and methods of application as external preparations, but differ mainly in whether the site of direct action is the hair or the scalp. In addition, "external preparations for skin" is a concept that includes "external preparations for scalp" and means an external preparation that acts directly on the skin, not limited to the scalp.

[0040] The method of the present invention includes a step of administering the composition of the present invention to a subject. The amount of D-chiro-inositol administered to a subject is not particularly limited, but is preferably 0.005 to 200 mg, more preferably 0.05 to 100 mg, and even more preferably 0.5 to 10 mg.

[0041] The number of times the composition of the present invention is administered to a subject is not particularly limited, but is preferably 1 to 6 times per day, more preferably 1 to 3 times per day, and even more preferably 1 to 2 times per day.

[0042] The subject to which the composition of the present invention is administered is not particularly limited, but examples include humans, and animals such as livestock and pets. EXAMPLES

[0043] The present invention will be described in more detail below with reference to examples, but the present invention is not limited to these examples.

[0044] The components used in this example are as follows: [D-chiro-inositol] D-chiro-inositol (manufactured by Wako Pure Chemical Industries, Ltd., hereafter abbreviated as "DCI") [Surfactants] HCO-10 (Polyoxyethylene (10) hydrogenated castor oil, HLB value: 6.5, manufactured by Nikko Chemicals) HCO-20 (Polyoxyethylene (20) hydrogenated castor oil, HLB value: 10.5, manufactured by Nikko Chemicals) HCO-40 (Polyoxyethylene (40) hydrogenated castor oil, HLB value: 12.5, manufactured by Nikko Chemicals) HCO-50 (Polyoxyethylene (50) hydrogenated castor oil, HLB value: 13.5, manufactured by Nikko Chemicals) HCO-60 (Polyoxyethylene (60) hydrogenated castor oil, HLB value: 14, manufactured by Nikko Chemicals) PPG-8 Ceteth-20 (addition polymerization of ethylene oxide and propylene oxide to cetanol, HLB value: 12.5, manufactured by Nikko Chemicals Co., Ltd., hereafter abbreviated as "PBC44") PPG-4 Ceteth-20 (Polyoxyethylene polyoxypropylene cetyl ether, HLB value: 16.5, manufactured by Nikko Chemicals Co., Ltd., hereinafter abbreviated as "PBC34") Polysorbate 80 (polyoxyethylene sorbitan oleate, HLB value: 15, manufactured by Nikko Chemicals) Glyceryl oleate (monoester of oleic acid and glycerin, HLB value: 2.5, manufactured by Nikko Chemicals) Polyglyceryl-2 oleate (ester of oleic acid and diglycerin, HLB value: 5.5, manufactured by Nikko Chemicals) Sodium lauryl sulfate (manufactured by Nikko Chemicals) Sodium lauroyl methyl taurate (manufactured by Nikko Chemicals) Stearamidopropyl dimethylamine (Nikko Chemicals) [water] purified water

[0045] Example 1 DCI was dissolved in purified water so that each component had the composition shown in Table 1 below, a surfactant was added, and the remaining volume was diluted with purified water and mixed to prepare each composition as a formulation.

[0046] A. Formulation stability testing The resulting formulations were evaluated for DCI precipitation at each type and content of surfactant by the following method. Three lots of each formulation were prepared, and DCI precipitation was induced by a low-temperature cycle (incubation at 5°C for 12 hours, followed by incubation at -20°C for 12 hours, repeated for 28 days), and the precipitation was evaluated visually based on the following criteria. The evaluation results are shown in Table 1 (N=3). No crystal precipitation was observed in any lot. "◎" Even in 1 lot, slight crystal precipitation was observed (〇) Even in one lot, a small amount of crystals were observed (△). Even in one lot, a large amount of crystals was observed (X).

[0047] B. Usability test The obtained preparations were evaluated for feel during application (roughness and stickiness) of the surfactant-containing preparation by the following method. Ten evaluation monitors applied 0.5 g of the formulation to the scalp and to the arms and evaluated the roughness and stickiness of the formulation when applied. Specifically, the evaluation was as follows. The roughness and stickiness were evaluated by conducting a questionnaire using a visual analogue scale that was scored as follows. <Feeling of use> Rough feeling No roughness, no problems with usability (1 point) The texture is very rough and is problematic in terms of usability (10 points) Sticky feeling There is a noticeable stickiness, but there are no problems with usability. "1 point" Very little stickiness, usability problematic (10 points) Next, the survey results were averaged and the degree of improvement (%) was calculated according to the following formula, and the evaluation results are summarized in Table 4 (N=10). Improvement rate (%) = 100 x (average of survey results for formulations without surfactants in Table 1 - average of survey results for formulations containing surfactants) / average of survey results for formulations without surfactants in Table 1 In the above formula, the degree of improvement was calculated by selecting formulations with the same DCI content for "formulations without surfactants in Table 1" and "formulations containing surfactants." Specifically, formulations with the same DCI content, either "5% by mass" or "0.1% by mass," were selected, and the degree of improvement was calculated as the relative value of the average questionnaire results for "formulations containing surfactants" when the average questionnaire results for "formulations without surfactants in Table 1" was set to 100.0.

[0048] [Table 1]

[0049] From the results in Table 1, it can be concluded that the precipitation of DCI can be effectively suppressed by adding a surfactant to the formulation. It was also confirmed that the roughness and stickiness caused by the DCI-containing formulation were improved by adding a surfactant.

Claims

1. D-chiro-inositol, a surfactant, and water; A composition (excluding compositions containing phospholipids) having a D-chiro-inositol content of 0.001 to 20% by mass.

2. The composition described in claim 1, wherein the HLB value of the surfactant is 2 to 17.

3. The composition described in claim 1 or 2, wherein the surfactant comprises a nonionic surfactant.

4. The composition of claim 3, wherein the nonionic surfactant comprises polyoxyethylene hydrogenated castor oil or polyoxyethylene polyoxypropylene alkyl ether.

5. An external preparation comprising the composition according to any one of claims 1 to 4.

6. A scalp topical preparation comprising the composition according to any one of claims 1 to 4.

Citation Information

Patent Citations

  • Hair growing agent

    JP1992202113A

  • Hair-growing agent

    JP2006028026A

  • Scalp cosmetic

    JP2009079018A

  • Hair grower

    JP2009108023A

  • Extract of eucalyptus young leaf and hair restorer

    JP2011132182A